As a Free StocksGuide user, you can view scores for all 7,031 stocks worldwide.
8 Analysts have issued a Cardiol Therapeutics Inc - Ordinary Shares - Class A forecast:
8 Analysts have issued a Cardiol Therapeutics Inc - Ordinary Shares - Class A forecast:
| Jun '25 |
+/-
%
|
||
| Revenue | - - |
-
|
|
| Gross Profit | - - |
-
|
|
| EBITDA | -29 -29 |
26%
26%
|
|
| EBIT (Operating Income) EBIT | -29 -29 |
26%
26%
|
|
| Net Profit | -27 -27 |
28%
28%
|
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Cardiol Therapeutics Inc. is a clinical-stage biotechnology company that focuses on the research and clinical development of anti-inflammatory therapies for the treatment of cardiovascular disease (CVD). Its product, CardiolRx, is a pharmaceutically produced extra strength oral cannabidiol formulation that is entering a Phase II/III outcomes study in hospitalized patients testing positive for the COVID-19 virus. The company was founded by David Elsley, Eldon Smith, and Anthony Bolton on January 19, 2017 and is headquartered in Oakville, Canada.
| Head office | Canada |
| CEO | David Elsley |
| Employees | 18 |
| Founded | 2017 |
| Website | www.cardiolrx.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


